IsoBlog
Stay updated with the latest advancements in radiopharmaceuticals, global oncology research, and Isotopia's expanding operations around the world.
Advancing Prostate Biopsy Accuracy: The Power of PSMA Molecular Imaging
PSMA imaging has recently become a major milestone in the examination, monitoring, and treatment of prostate cancer patients, espe...
Read MorePSMA-11 PET/CT in Prostate Cancer Recurrence: Five-Year Clinical Outcomes and Long-Term Impact
PSMA-11 PET/CT in Prostate Cancer Recurrence: Five-Year Clinical Outcomes and Long-Term Impact Introduction: A New Era in Imaging...
Read MorePrecision Mapping for Personalized Therapy:The Triple-Tracer Roadmap to Cocktail RLT
PSMA-11 PET/CT in Prostate Cancer Recurrence: Five-Year Clinical Outcomes and Long-Term Impact Introduction: A New Era in Imaging...
Read More99mTc-PSMA Intraoperative Use - Part 2
99mTc-PSMA Radioguided Surgery in Prostate Cancer: A Comprehensive Review of Intraoperative Strategies, Limitations, and Innovatio...
Read MoreBeyond Lutetium: The Auger Electron Advantage of Terbium-161 in the VIOLET Trial
We are entering a new era of radioligand therapy, moving from Lutetium-177 to Terbium-161 (161Tb). As noted by Dr. Steven H. Lian...
Read More18F-FDOPA PET/CT in the Evaluation of Recurrent Glioblastoma Multiforme
Based on the cited paper, it is clear that [18F]-FDOPA Positron Emission Tomography/ Computed Tomography (PET/CT) plays a crucial ...
Read MoreIntra-arterial Radiotherapy for Prostate Cancer—Revolutionary or Reckless?
Introduction: A New Frontier in Prostate Cancer Treatment A recent study published in the journal Radiology is paving the way f...
Read More99mTc-PSMA Intraoperative Use - Part 1
99mTc-PSMA Radioguided Surgery in Prostate Cancer: A Comprehensive Review of Intraoperative Strategies, Limitations, and Innovatio...
Read MoreMarking International Parkinson's Disease Day: The Power of [18F]-FDOPA PET/CT in Diagnosis
As we observe International Parkinson's Disease Day, it is important to reflect on the advancements in diagnosing and understandin...
Read MoreThe Role of Aseptic Manufacturing in Ensuring Drug Safety
In the ever-evolving healthcare landscape, the development of cutting-edge technologies—such as gels, solutions, liposomes, lyophi...
Read MoreUnveiling the Significance of SUV Measure in Theranostics
’Simple Usable Value’ or ‘Smart Utility Vehicle’ in Medicine: The Importance of the SUV Measure in Theranostics Abstract: The S...
Read MorePSMA-11: The Gold Standard in Prostate Cancer Imaging
Prostate cancer continues to pose a significant health challenge, impacting 1 in 8 men in the United States [1]. Early and accurat...
Read MoreTHE CLINICAL UTILITY OF PSMA-11
Prostate cancer remains one of the most common malignancies among men, and for many, the challenge lies in managing biochemical re...
Read More161-Terbium for PRRT in Neuroendocrine Tumors
PRRT (Peptide Receptor Radionuclide Therapy) is a type of targeted cancer therapy that treats neuroendocrine tumors (NETs) by deli...
Read MoreNuclear Medicine role in Neuroendocrine Tumors
Abstract:Neuroendocrine Tumors (NETs) are cancers that originate from specialized cells called neuroendocrine cells, which have c...
Read MoreTerbium 161 for Targeted Radionuclide Therapy in Oncology
Abstract:Terbium-161 is a promising candidate for clinical translation because it emits short-ranged conversion and Auger electron...
Read MoreOvercoming Lutetium-177 Production and Supply Challenges
Published by Isotopia, 21th April 2022 Published by Isotopia, 21th April 2022 Lutathera and Lu-PSMA 617 are FDA-appr...
Read MoreNuclear imaging in Parkinson's disease- The past, the present, and the future
Published by Isotopia, 16th May 2022 Published by Isotopia, 16th May 2022 We are proud to share this exciting article written ...
Read MorePSMA theranostics in tumors other than prostate cancer
The role of PSMA theranostics in treating prostate cancer is well known. Non-prostatic diseases exhibiting a PSMA uptake on PET a...
Read MoreTHE POTENTIAL ROLE OF PSMA THERANOSTICS IN CANCER OF THE ORAL CAVITY
Cancer of the oral cavity is one of the most common malignancies, especially in developing countries, but also in the developed wo...
Read MoreIs there a future for PSMA theranostics in Osteosarcoma?
Prostate-specific membrane antigen (PSMA) theranostics has shown promising results in both diagnosis and treatment of prostate can...
Read MoreThe unmet need for 177-Lu-PSMA radioligand therapy in America for mCRPC patients
Based on findings from the VISION trial [1], the FDA approved 177Lu-PSMA-617 in March 2022 for the treatment of patients with PSMA...
Read MoreThe Future of Theranostics in Prostate Cancer- PSMA RLT and Combination Therapy
PSMA RLT and Combination Therapy Abstract: Prostate cancer remains a significant healthcare challenge worldwide, necessitating ...
Read MoreRadiopharmacy and Radiobiology Aspects for 161-Terbium
Abstract: From a radiopharmaceutical point of view, 161-Terbium (161Tb) and 177-Lutetium (177Lu) are both radiolanthanides that sh...
Read MoreTerbium-161 Radionuclide Therapy in Prostate Cancer
Castration resistance is a term used to describe the development of resistance to androgen deprivation therapy (ADT) in prostate c...
Read MoreproPSMA study
The “proPSMA” study results proved the superiority of 68Ga-PSMA imaging over conventional imaging with CT and Bone Scan in Prosta...
Read MoreVision study - Research on Prostate Cancer
177Lu-PSMA-617 radioligand therapy in mCRPC - VISION phase 3 trial The results from the “ProPSMA” Study, that was recently publis...
Read MoreLutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Take home message: Take home message: The vision study is an international phase 3 trial Comparing between best medical c...
Read MoreProstate cancer
Innovative metastatic prostate cancer treatment with 177-Lu-PSMA.Prostate cancer is the most common cancer in older men (over 50) ...
Read MorePERSONALIZED NUCLEAR MOLECULAR CANCER THERAPY
For decades, physicians and patients knew three classic treatments for cancer:SurgeryChemotherapyRadiation therapyNew times have c...
Read MoreLutetium 177 production (Lu177 production)
Carrier Added (CA) and Non-Carrier Added (NCA) The production of 177-Lu 177-Lu is a fully synthetic isotope. there are 2 ways t...
Read More18F-DOPA use in Parkinsonism
On October 10, 2019, the FDA approved the use of 18F-DOPA in positron emission tomography to visualize dopaminergic nerve terminal...
Read More